ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Tumor necrosis factor (TNF)"

  • Abstract Number: 94 • 2019 ACR/ARP Annual Meeting

    Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells

    Shotaro kawano1, Hiroki Mitoma 2, Shoichiro Inokuchi 3, Masahiro Ayano 2, Yasutaka Kimoto 4, Mitsuteru Akahoshi 2, Yojiro Arinobu 2, Koichi Akashi 2, Takahiko Horiuchi 5 and Hiroaki Niiro 6, 1Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 2Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, 3Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Fukuoka, Japan, 4Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 5Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, 6Clinical Education Centre, Kyushu University Hospital, Fukuoka, Japan, Fukuoka, Japan

    Background/Purpose: Tumor Necrosis Factor (TNF) α is a multifunctional cytokine with pro-inflammatory and anti-inflammatory characteristics. Regulatory T cells (Treg) express a remarkably high level of…
  • Abstract Number: 106 • 2019 ACR/ARP Annual Meeting

    Increased T Cell Polyreactivity with Marked Accumulation of TNF-α DP (CD4+CD8+) in the Synovial Tissue of pre-RA, Arthralgia Subjects

    Achilleas Floudas1, Douglas Veale 2 and Ursula Fearon 3, 1Trinity Biomedical Sciences Institu, DUBLIN, Ireland, 2EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland, 3Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland

    Background/Purpose: Effective treatment of Rheumatoid arthritis (RA) patients is achievable within a short window of opportunity following diagnosis. Identification of pathogenic immune mechanisms at a…
  • Abstract Number: 614 • 2019 ACR/ARP Annual Meeting

    Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data

    Bon San Koo1, Yu-Cheol Lim 2, Min-Young Lee 3, Ja-Young Jeon 4, Hyun-Jeong Yoo 5, In-Sun Oh 2, Ju-Young Shin 2 and Tae-Hwan Kim 6, 1Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, 2School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea, 3VIAplus, Siheung, Republic of Korea, 4Pfizer Inc, Seoul, Republic of Korea, 5Pfizer Korea, Seoul, Republic of Korea, 6Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

    Background/Purpose: Tapering of tumor necrosis factor (TNF) inhibitors may be considered in patients with ankylosing spondylitis (AS) with low disease activity. However, there is still…
  • Abstract Number: 752 • 2019 ACR/ARP Annual Meeting

    Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis

    Corrado Campochiaro1, Alessandro Tomelleri 2, Silvia Sartorelli 3, Giulio Cavalli 2, De Luca Giacomo 4, Elena Baldissera 2 and Lorenzo Dagna 2, 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, 2Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, 3Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, 4Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Milan, Italy

    Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis affecting mainly young women. Biologic agents are currently use to treat refractory TA patients but no…
  • Abstract Number: 772 • 2019 ACR/ARP Annual Meeting

    The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)

    Shoko Tsuji1, Hidenori Matsuzaki 2, Masanori Iseki 3, Akiko Nagasu 1, Hiroyasu Hirano 1, Katsuhiko Ishihara 4, Naoyasu Ueda 5, Yoshitaka Honda 6, Takahiko Horiuchi 7, Ryuta Nishikomori 8, Yoshitaka Morita 1 and Tomoyuki Mukai 9, 1Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, 2Department of Life Sciences, Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, shobara, Hiroshima, Japan, 3Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, 4Department of Immunology and Molecular Genetics, Kurashiki, Okayama, Japan, 5Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, 6Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, 7Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, 8Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Fukuoka, Japan, 9Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Okayama, Japan

    Background/Purpose: TNF Receptor-Associated Periodic Syndrome (TRAPS) is one of the autoinflammatory diseases. TRAPS is caused by heterozygous mutations in the TNFRSF1A gene. Although more than…
  • Abstract Number: 785 • 2019 ACR/ARP Annual Meeting

    Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience

    Muhammad Shipa1, Anastasia-vasiliki Madenidou 2, vera Choida 1, Anna Radziszewska 3, corinne fisher 4, coziana ciurtin 1, maria Leandro 1 and Debajit Sen 1, 1Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, London, United Kingdom, 2Centre for Adolescent Rheumatology, University College London London, UK, LOndon, 3University College London, London, United Kingdom, 4Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, lonodn, United Kingdom

    Background/Purpose: Biologics have transformed the treatment of Juvenile idiopathic arthritis (JIA) and escalation toTumour Necrosis Factor - α inhibitors (TNFi) after failure of methotrexate (MTX)…
  • Abstract Number: 929 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study

    Stanley Cohen1, Katie Tuckwell 2, Rebecca Kunder 2, Tamiko Katsumoto 3, Rui Zhao 2, Alberto Berman 4, Nemanja Damjanov 5, Dmytro Fedkov 6, Slawomir Jeka 7 and Mark Genovese 3, 1Metroplex Clinical Research Center, Dallas, TX, 2Genentech, Inc., South San Francisco, CA, 3Stanford University, Stanford, CA, 4Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, 5Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, 6Bohomolets National Medical University, Kyiv, Ukraine, 7University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland

    Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an orally administered, highly selective, non-covalent, and reversible small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK).1 We report the efficacy…
  • Abstract Number: 947 • 2019 ACR/ARP Annual Meeting

    TNF Inhibitor Treatment and Dramatic Stroke Risk Reduction in Patients with Deficiency of Adenosine Deaminase 2

    Ryan Laird1, Patrycja Hoffmann 2, Karyl Barron 2, Deborah Stone 2, Michele Nehrebecky 3, Anne Jones 2, Tina Romeo 2, Camilo Toro 3, Arianne Soldatos 4, Cornelia Cudrici 3, Daniel Kastner 2 and Amanda Ombrello 2, 1National Institues of Health, Bethesda, 2National Institutes of Health, Bethesda, MD, 3National Institutes of Health, Bethesda, 4NIH/NINDS, Bethesda

    Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease caused by biallelic loss-of-function mutations in the ADA2 gene . Over 60 pathogenic…
  • Abstract Number: 1012 • 2019 ACR/ARP Annual Meeting

    Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis

    Yannick Degboe 1, Flavia Sunzini 1, Iain McInnes 2 and Carl Goodyear1, 1University of Glasgow, Glasgow, United Kingdom, 2Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: PsA is associated with bone erosion and inflammation-induced bone loss. This process is mediated by osteoclasts, and modulated by inflammatory cytokines (i.e. TNF, IL-1,…
  • Abstract Number: 1871 • 2013 ACR/ARHP Annual Meeting

    Progranulin Directly Binds To The CRD 2 and CRD3 Of TNFR Extracellular Domains

    Jinlong Jian1, Shuai Zhao1, Qingyun Tian1, Elena Gonzalez Gugel2, Jyoti Mundra2, Sardar MZ Uddin2, Ben Liu3, Brendon Richbourgh2, Ryan Brunetti2, Gerald Chan4, Carolyn Green5 and Chuanju Liu1, 1Orthopaedic Surgery, NYU Hospital for Joint Diseases, New York, NY, 2NYU Hospital for Joint Diseases, New York, NY, 3NYU Hospital for Joint Diseases, New York Univerity, NY, 4Atreaon, Boston, MA, 5Atreaon, Boston, NY

    Background/Purpose: We previously reported that Progranulin (PGRN) bound to TNF receptors (TNFR) and was therapeutic in inflammatory arthritis (Tang, W., et al, Science, 2011). PGRN…
  • Abstract Number: 472 • 2012 ACR/ARHP Annual Meeting

    More Positive Expectations of Treatment with Golimumab for Rheumatoid Arthritis Are Associated with Greater Improvement in Clinical Outcomes

    Bhaskar Dasgupta1, Bernard Combe2, Ingrid Louw3, Sarvajeet Pal4, Jürgen Wollenhaupt5, Cristiano Zerbini6, Andre D. Beaulieu7, Hendrik Schulze-Koops8, Patrick Durez9, W. Bensen10, V. Wolff11, Ruji Yao12, Holly Weng12 and Nathan Vastesaeger13, 1Southend University Hospital, Westcliff-on-Sea, United Kingdom, 2Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, 3Panorama Medical Centre, Cape Town, South Africa, 4Advance Rheumatology Clinic, Hyderabad, India, 5Schön-Klinik, Hamburg, Germany, 6Centro Paulista de Investigações, Sao Paulo, Brazil, 7Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, 8University of Munich, Munich, Germany, 9UCL Saint-Luc, Brussels, Belgium, 10St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 11Hospital del Salvador, Santiago, Chile, 12Merck Sharp & Dohme, Kenilworth, NJ, 13Merck Sharp & Dohme, Brussels, Belgium

    Background/Purpose: Little is known about how patient and physician expectations relate to clinical outcomes. This study investigated the expectations that patients and physicians have at…
  • Abstract Number: 471 • 2012 ACR/ARHP Annual Meeting

    Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs

    Bernard Combe1, Bhaskar Dasgupta2, Ingrid Louw3, Sarvajeet Pal4, Jürgen Wollenhaupt5, Cristiano Zerbini6, Andre D. Beaulieu7, Hendrik Schulze-Koops8, Patrick Durez9, Ruji Yao10, Nathan Vastesaeger11 and Holly Weng10, 1Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, 2Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, 3Panorama Medical Centre, Cape Town, South Africa, 4Advance Rheumatology Clinic, Hyderabad, India, 5Schön-Klinik, Hamburg, Germany, 6Centro Paulista de Investigações, Sao Paulo, Brazil, 7Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, 8University of Munich, Munich, Germany, 9UCL Saint-Luc, Brussels, Belgium, 10Merck Sharp & Dohme, Kenilworth, NJ, 11Merck Sharp & Dohme, Brussels, Belgium

    Background/Purpose: This study evaluated golimumab (GLM) as add-on therapy in patients with active RA despite treatment with non-biologic DMARDs. Two GLM treatment strategies (subcutaneous [SC]…
  • Abstract Number: 549 • 2012 ACR/ARHP Annual Meeting

    A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II

    Joachim Sieper1, Jan Lenaerts2, Jürgen Wollenhaupt3, Vadim Mazurov4, L. Myasoutova5, Sung-Hwan Park6, Yeong W. Song7, Ruji Yao8, Denesh Chitkara9 and Nathan Vastesaeger10, 1Charité, University Medicine Berlin, Berlin, Germany, 2Reuma-instituut, Hasselt, Belgium, 3Schön-Klinik, Hamburg, Germany, 4St. Petersburg Medical Academy, St. Petersburg, Russia, 5Kazan State Medical University, Kazan, Russia, 6Catholic University of Korea, Seoul, South Korea, 7Seoul National University, Seoul, South Korea, 8Merck Sharp & Dohme, Kenilworth, NJ, 9Merck Sharp and Dohme, Kenilworth, NJ, 10Merck Sharp & Dohme, Brussels, Belgium

    Background/Purpose: In patients with axial SpA who have achieved partial remission, it is unclear whether continuous treatment with NSAIDs is superior to stopping treatment. Objectives:…
  • Abstract Number: 779 • 2012 ACR/ARHP Annual Meeting

    Changes in Active Inflammatory Lesions Assessed by Magnetic Resonance Imaging: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial

    Joachim Sieper1, Jan Lenaerts2, Jürgen Wollenhaupt3, Vadim Mazurov4, L. Myasoutova5, Sung-Hwan Park6, Yeong W. Song7, Ruji Yao8, Denesh Chitkara9 and Nathan Vastesaeger10, 1Charité, University Medicine Berlin, Berlin, Germany, 2Reuma-instituut, Hasselt, Belgium, 3Schön-Klinik, Hamburg, Germany, 4St. Petersburg Medical Academy, St. Petersburg, Russia, 5Kazan State Medical University, Kazan, Russia, 6Catholic University of Korea, Seoul, South Korea, 7Seoul National University, Seoul, South Korea, 8Merck Sharp & Dohme, Kenilworth, NJ, 9Merck Sharp and Dohme, Kenilworth, NJ, 10Merck Sharp & Dohme, Brussels, Belgium

    Background/Purpose: Few studies have evaluated changes in active inflammation of spine and sacroiliac (SI) joints by MRI during long-term treatment for axial SpA, and no…
  • Abstract Number: 834 • 2012 ACR/ARHP Annual Meeting

    Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Significantly Reduces Tumour-Necrosis-Factor-Alpha and Demonstrates Efficacy in Patients with Active Rheumatoid Arthritis: A Proof-of-Concept, Double-Blind, Randomised Trial

    Anita Kåss1, Øystein T. Førre2, Morten Fagerland3, Hans Christian Gulseth4, Peter Torjesen5 and Ivana Hollan6, 1University of Oslo, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3Department of Biostatistics, Oslo University Hospital, Oslo, Norway, 4Rheumatology, Betanien Hospital, Skien, Norway, 5Department of Endocrinology, Oslo University Hospital, Oslo, Norway, 6Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway

    Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1) and therefore might…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.